Characteristic | No.(%) | CDC6 | CDT1 | MCM2 | CDC45 |
---|---|---|---|---|---|
Age (years) | |||||
Median 54 (range 17–82) |  |  |  |  |  |
Sex | Â | Â | Â | Â | Â |
Male | 33(52%) | 2.17E-03 ± 8.24E-04 | 1.10 ± 0.44 | 1.20 ± 0.24 | 2.17 ± 0.41 |
Female | 31(48%) | 6.28E-03 ± 1.97E-03 | 1.04 ± 0.34 | 1.28 ± 0.29 | 2.67 ± 0.89 |
Epithelial dysplasia (precancerous, n = 31) | |||||
Mild | 8(26%) | 4.68E-04 ± 1.42E-04 | 0.64 ± 0.14 | 0.19 ± 0.05 | 0.35 ± 0.72 |
Moderate | 8(26%) | 6.59E-03 ± 3.20E-03 | 0.99 ± 0.20 | 1.03 ± 0.18 | 2.29 ± 0.85 |
Severe | 15(48%) | 8.28E-03 ± 3.40E-03 | 1.94 ± 0.36 | 2.48 ± 0.35 | 3.32 ± 0.54 |
Histological grade (SCC, n = 33) | |||||
G1 | 13(40%) | 6.87E-03 ± 2.67E-03 | 0.92 ± 0.19 | 1.15 ± 0.22 | 2.48 ± 0.82 |
G2 | 10(30%) | 7.87E-03 ± 6.51E-04 | 0.72 ± 0.17 | 0.99 ± 0.30 | 1.97 ± 0.59 |
G3 | 10(30%) | 8.61E-03 ± 1.30E-03 | 1.40 ± 0.30 | 1.73 ± 0.73 | 2.45 ± 0.13 |
T-stage | |||||
T1 | 10(34%) | 7.61E-03 ± 4.45E-03 | 1.01 ± 0.27 | 0.71 ± 0.20 | 3.17 ± 0.93 |
T2 | 19(66%) | 5.02E-03 ± 7.62E-04 | 0.94 ± 0.14 | 1.56 ± 0.42 | 1.57 ± 0.44 |
Lymph node metastases | |||||
N0 | 12(41%) | 6.11E-04 ± 1.66E-04 | 0.74 ± 0.16 | 0.60 ± 0.15 | 1.27 ± 0.35 |
N1 | 11(38%) | 3.50E-03 ± 1.02E-03 | 0.90 ± 0.15 | 1.03 ± 0.64 | 2.00 ± 0.52 |
N2 | 6(21%) | 1.02E-02 ± 7.03E-03 | 1.28 ± 0.28 | 2.00 ± 0.42 | 3.54 ± 0.15 |
Clinical stage | |||||
I | 4(13%) | 4.21E-04 ± 3.08E-04 | 0.89 ± 0.14 | 0.15 ± 0.04 | 1.13 ± 0.36 |
II | 8(28%) | 8.02E-04 ± 1.13E-04 | 0.74 ± 0.16 | 0.85 ± 0.21 | 1.55 ± 0.46 |
III | 11(38%) | 3.50E-03 ± 1.02E-03 | 1.07 ± 0.28 | 1.03 ± 0.64 | 2.01 ± 0.52 |
IV | 6(21%) | 1.02E-02 ± 7.03E-03 | 1.78 ± 0.82 | 2.00 ± 0.42 | 3.54 ± 0.15 |